Skip to contentK
Kyntra Bio, Inc.
K
KYNBKyntra Bio, Inc. Q2 2023 · 10-Q
Revenue$44.32M$44.32M+48.7% vs Q2 2022 Net Income-$87.68M-$87.68MN/M vs Q2 2022 EPS Diluted-$0.90-$0.90N/M vs Q2 2022 Operating Income-$88,048,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$111,564,000N/M Margins · derivedOperating margin-198.7%+63.8 pt vs Q2 2022
Net margin-197.8%+45.8 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 7, 2023 · 38 d after period end